Forskning - International Huntington Association

SOM Biotech offentliggør resultater af fase 2b-studie

SOM Biotech presents the Phase 2b study results with SOM3355 demonstrating a unique profile with robust improvements of chorea in Huntington’s Disease Patients and a safe profile with no somnolence, […]

PTC Therapeutics indgår en global licens- og samarbejdsaftale med Novartis om PTC518 Huntingtons sygdomsprogram

December 2, 2024 – PTC to receive $1.0B in cash at closing –– PTC is eligible to receive up to $1.9B in development, regulatory and sales milestones –– PTC to share profits in the U.S. and […]

Sage Therapeutics indstiller udviklingen af dalzanemdor i HS

The Phase 2 DIMENSION Study did not meet its primary endpoint Dalzanemdor was generally well-tolerated; no new safety signals were observed Based on these data, the Company does not plan […]

LoQus23 Therapeutics annoncerer finansiering på 35 millioner pund for at fremme et nyt lægemiddel, der har til formål at hæmme somatisk ekspansion i Huntingtons sygdom

Cambridge, UK, 2 October 2024 – LoQus23 Therapeutics Ltd (“LoQus23”), a private biotechnology company investigating small molecule drugs that could stop DNA instability and slow neurodegeneration in Huntington’s Disease, myotonic dystrophy […]

Prilenias pridopidin til Huntingtons sygdom godkendt til gennemgang af europæisk markedsføringstilladelse

Prilenia, a clinical stage biotechnology company focused on the urgent mission to develop novel therapeutics to slow the progression of neurodegenerative diseases and neurodevelopmental disorders, has filed a European Marketing […]

uniQure annoncerer en positiv opdatering af foreløbige data, der viser en opbremsning af sygdomsudviklingen i fase I/II-forsøg med AMT-130 til HS

"Vi er meget tilfredse med disse nye data, der viser en statistisk signifikant, dosisafhængig opbremsning af udviklingen af Huntingtons sygdom og en sænkning af NfL i CSF efter 24 måneder," [...].

Wave Life Sciences annoncerer positive resultater fra fase 1b/2a SELECT-HD-forsøget med den første kliniske demonstration af allel-selektiv mutant Huntingtin-sænkning i Huntingtons sygdom

Today, Wave Life Sciences announced positive results from SELECT-HD, our Phase 1b/2a placebo-controlled trial evaluating the investigational therapy WVE-003. These results demonstrate that WVE-003 selectively lowers toxic, mutant huntingtin (mHTT) […]

Kategori: Forskning